3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Margins of Excision
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Lesion
1
Prostatic Neoplasms
1
Nevus, Pigmented
1
Nephrolithiasis
1
Multicystic renal dysplasia, bilateral
1
Melanoma
1
Hematuria
1
Carcinoma, Basal Cell
1
Adenocarcinoma
1
Interventions
pembrolizumab
5
enfortumab vedotin
3
Gemcitabine
3
dodecyl maltoside
2
Sunitinib
2
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tucatinib
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
palbociclib
1
niraparib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
cabozantinib
1
Valproic Acid
1
Urinary Diversion
1
Trastuzumab
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Rivaroxaban
1
Ringer's acetate
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Nivolumab
1
Multiparametric Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Microscopy, Confocal
×
1 year
×
Clear all
NCT02276924
2025-12-24
UROVISIO
Lille Catholic University
Phase NA
Completed
29 enrolled